NEWPORT BEACH, Calif. / Dec 13, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non-executive employees of... Read More

Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme ® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug... Read More

NEWPORT BEACH, Calif. / Nov 01, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here . A replay of the... Read More

NEWPORT BEACH, Calif. / Oct 31, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme ® (pronounced “esteem”), branded as Evolysse ™ in the U.S. market. This... Read More

Achieves 2 Million Jeuveau ® Redemptions Anticipates Launch of Club Evolus ™ , the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024 NEWPORT BEACH, Calif. / Oct 29, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and... Read More

NEWPORT BEACH, Calif. / Oct 23, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30... Read More

NEWPORT BEACH, Calif. / Oct 11, 2024 / Business Wire / Evolus, Inc . (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the... Read More

NEWPORT BEACH, Calif. / Sep 27, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board... Read More

NEWPORT BEACH, Calif. / Sep 06, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024. The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. The Nasdaq closing bell... Read More

NEWPORT BEACH, Calif. / Aug 09, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting the grant in August of... Read More

Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Quarter of Profitability 1 with Positive Non-GAAP Operating Income of $1.1 Million for Q2 2024 Premarket Approval (PMA) Application Submitted to the... Read More

NEWPORT BEACH, Calif. / Jul 31, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The event will be hosted at the “SECOND Floor” venue located at 849 6th Ave, New York, NY... Read More

Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals NEWPORT BEACH, Calif. / Jul 30, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the... Read More

NEWPORT BEACH, Calif. / Jul 17, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m.... Read More

NEWPORT BEACH, Calif. / Jul 01, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus’ Compensation... Read More

NEWPORT BEACH, Calif. / Jun 24, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). “We... Read More

Launching in one of the five largest aesthetic toxin injectable markets in Europe 1 as part of the company’s geographic expansion strategy Evolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionals NEWPORT BEACH, Calif. / Jun 12, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially... Read More

NEWPORT BEACH, Calif. / Jun 07, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an aggregate of 29,546 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non-executive employees of the... Read More

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepoints for the entire 12-month study period Evolus dermal filler, Evolysse™ Smooth, met primary endpoint of non-inferiority and demonstrated... Read More

David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau ® is the fastest growing aesthetic toxin in the U.S. for the last three years 1 NEWPORT BEACH, Calif. / May 15, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer... Read More

NEWPORT BEACH, Calif. / May 10, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the... Read More

Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability 1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse ® Lift and Smooth fillers, FDA Submission Expected within Next 90 Days Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End Remains on Track... Read More

NEWPORT BEACH, Calif. / Apr 23, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET... Read More

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual Meeting Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1-point Glabellar Line Scale (GLS) improvement and return to baseline value using the Global Aesthetic Improvement Scale NEWPORT BEACH, Calif. /... Read More

NEWPORT BEACH, Calif. / Apr 12, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of Evolus and an aggregate of 20,971 restricted stock units (RSUs) of the company’s common stock to 10 newly hired non-executive employees of the... Read More

NEWPORT BEACH, Calif. / Mar 26, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April: Event: The 23 rd Annual Needham Virtual Healthcare Conference Date: Tuesday, April 9 th , 2024 Time: 9:30 – 10:10 AM ET The fireside chat can be accessed... Read More

NEWPORT BEACH, Calif. / Mar 11, 2024 / Business Wire / Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be approximately $50.0... Read More

NEWPORT BEACH, Calif. / Mar 08, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units (RSUs) of the company’s common stock to 8 newly hired non-executive employees of the... Read More

Evolus dermal filler product (Evolysse™/Estyme ® Lift) demonstrates statistical superiority at 3 and 6 months compared to Restylane-L with respect to improvement in nasolabial fold severity The European Lift study met the primary endpoint of non-inferiority NEWPORT BEACH, Calif. / Mar 01, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of... Read More

NEWPORT BEACH, Calif. / Feb 27, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12 th , 2024 Time: 10:00-10:30am ET Event: The Barclays 26 th Annual... Read More

NEWPORT BEACH, Calif. / Feb 22, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live... Read More

NEWPORT BEACH, Calif. / Feb 09, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 15,101 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board... Read More

Preliminary Unaudited Net Revenue of Approximately $61 Million for the Fourth Quarter 2023, Representing 40% Growth Over the Prior Year Quarter and a 22% Increase Over the Prior Sequential Quarter Preliminary Unaudited Net Revenue of Approximately $202 Million for the Full-Year 2023, Representing 36% Growth Over the Prior Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Which Represents 26% to 31% Growth From... Read More

NEWPORT BEACH, Calif. / Jan 12, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 89,770 shares of Evolus and an aggregate of 82,730 restricted stock units (RSUs) of the company’s common stock to six newly hired non-executive employees of the... Read More

NEWPORT BEACH, Calif. / Jan 04, 2024 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and... Read More

Exclusive Distributor Agreement with Symatese Broadens Evolus’ Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and Europe European Regulatory Approvals Anticipated in Second Half of 2024 Company Continues to Expect to be Fully Funded to Profitability 1 NEWPORT BEACH, Calif. / Dec 20, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic... Read More

NEWPORT BEACH, Calif. / Dec 08, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in December of an aggregate of 28,328 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the... Read More

NEWPORT BEACH, Calif. / Nov 10, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 63,703 shares of Evolus and an aggregate of 70,320 restricted stock units (RSUs) of the company’s common stock to 8 newly hired non-executive employees... Read More

Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million Operating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability 1 with Existing Liquidity “Extra-Strength” 40U Formulation of Jeuveau ® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023... Read More

“Extra-strength” 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment 40U results indicate a similar safety profile to lower dose arms in the study NEWPORT BEACH, Calif. / Nov 06, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic... Read More

NEWPORT BEACH, Calif. / Nov 01, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November. Event: Stifel 2023 Healthcare Conference Date: Wednesday, November 15, 2023 Time: 11:30 AM ET Event: 6 th Annual Evercore ISI... Read More

NEWPORT BEACH, Calif. / Oct 25, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to... Read More

Oral abstract will be presented on Friday, November 3, 2023 NEWPORT BEACH, Calif. / Oct 25, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023... Read More

NEWPORT BEACH, Calif. / Sep 29, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,562 shares of Evolus and an aggregate of 46,481 restricted stock units (RSUs) of the company’s common stock to 17 newly hired non-executive employees of the... Read More

NEWPORT BEACH, Calif. / Aug 29, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September. Event: H.C. Wainwright 25 th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Time: 11:00 – 11:30 am ET... Read More

NEWPORT BEACH, Calif. / Aug 23, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common stock and 63,358 restricted stock units (RSUs) to Tomoko Yamagishi-Dressler,... Read More

Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category NEWPORT BEACH, Calif. / Aug 21, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two... Read More

Company launches bold rebrand of Jeuveau ® (prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated exclusively for aesthetics Jeuveau ® has been the fastest-growing neurotoxin in the U.S. for two consecutive years in 2021 and 2022 1 NEWPORT BEACH, Calif. / Aug 08, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a... Read More

Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022 Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million On Track to Achieving Sustained Profitability with Existing Cash NEWPORT BEACH, Calif. / Aug 02, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter... Read More

Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter’s Growth Rate Achieved Record Growth and All-time Highs in New Accounts, and Consumer Loyalty Enrollments and Redemptions NEWPORT BEACH, Calif. / Jul 27, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a... Read More

NEWPORT BEACH, Calif. / Jul 26, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in Canaccord Genuity’s 43 rd Annual Growth Conference in Boston. Event: Canaccord Genuity’s 43rd Annual Growth Conference Date: Wednesday, August 9, 2023 Time: 8:30 – 8:55... Read More

NEWPORT BEACH, Calif. / Jul 19, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to... Read More

Launching in the fourth largest aesthetic toxin injectables market in Europe 1 is part of the company’s geographic expansion strategy GP Dermal Solution will serve as distribution partner in Italy NEWPORT BEACH, Calif. / Jun 29, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced the commercial launch of Nuceiva® (botulinum toxin type A)... Read More

NEWPORT BEACH, Calif. / Jun 22, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau ® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively... Read More

NEWPORT BEACH, Calif. / Jun 08, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced it recently completed the one-millionth Jeuveau ® redemption through its Evolus Rewards™ patient loyalty program. “We designed Evolus Rewards™ as the first text-based loyalty program in the aesthetic space to create a connection with the... Read More

Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million Raises 2028 Revenue Outlook from $500 Million to $700 Million Driven by Addition of Evolysse™ Dermal Filler Line Representing a 29% CAGR Fully Funded to Profitability, Including the Dermal Filler Investment, by Utilizing Remaining $50 Million of Pharmakon Credit Facility NEWPORT BEACH, Calif. / May... Read More

Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 Raises 2028 Revenue Outlook from $500 Million to $700 Million Representing a 29% CAGR Highly Capital Efficient Deal Structure Funded Through $50 Million Pharmakon Tranche; Company Expects to Remain Fully Funded to Profitability Symatese, with 25 Years of Experience, Developed the XpresHAn Technology™/OBT ® for the Latest Generation Restylane... Read More

NEWPORT BEACH, Calif. / May 05, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to... Read More

NEWPORT BEACH, Calif. / Mar 08, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. The results were consistent with the previously reported preliminary unaudited results announced on January 18,... Read More

NEWPORT BEACH, Calif. / Feb 28, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida. Event: Barclays Global Healthcare Conference Date: Tuesday, March 14, 2023 Time: 2:35-3:00pm... Read More

NEWPORT BEACH, Calif. / Feb 27, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has commenced the commercial launch of Nuceiva ® (botulinum toxin type A) in Germany and Austria, and is now available for direct order and delivery to customers. Nuceiva ® is approved by the European Commission for the temporary... Read More

NEWPORT BEACH, Calif. / Feb 22, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023, after the U.S. financial markets close. Evolus management will host a conference call... Read More

NEWPORT BEACH, Calif. / Feb 10, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, issued the following statement. Earlier today, the Seoul Central District Court ruled in favor of Medytox, Inc. related to a long-standing trade secret dispute between Medytox and Daewoong Pharmaceutical Co. Ltd. The recent ruling by the... Read More

NEWPORT BEACH, Calif. / Jan 31, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. Event: SVB Securities Global Biopharma Conference. Date: Tuesday, February 14, 2023 Time: 11:20-11:50 am ET An... Read More

“Extra-strength” 40U formulation achieves one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance Results indicate a favorable safety profile; no serious adverse events reported and 88% of all adverse events were mild Potential new “extra-strength” formulation would expand Evolus' Jeuveau ® offering Trial completion expected mid-2023; final... Read More

Australia among the largest countries in the world for aesthetic neurotoxins 1 NEWPORT BEACH, Calif. / Jan 23, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva ® (prabotulinumtoxinA)▼, a neurotoxin... Read More

Oral presentation for longer duration formulation on Saturday, January 28, 2023 Investor webcast to discuss findings on Monday, January 30, 2023 NEWPORT BEACH, Calif. / Jan 23, 2023 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, will present interim findings from a Phase 2 study evaluating the safety, efficacy and... Read More

Q4 2022 Preliminary Unaudited Net Revenue of Approximately $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Preliminary Unaudited Net Revenue of Approximately $148.6 Million, Up 49% Over 2021 2023 Net Revenue Expected to be $180 to $190 Million Projecting Profitability, Positive Non-GAAP Operating Income 1 in Q4 2023 Estimating Organic Net Revenue to Reach $500 Million by 2028, a 22% CAGR Evolus, Inc. (NASDAQ: EOLS), a... Read More

NEW BRUNSWICK, N.J. , Dec. 7, 2022 /PRNewswire/ -- Pipeline Medical , a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medical professionals around the country, recently announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus, Inc. (NASDAQ: EOLS). Launched in 2019, Jeuveau® is a botulinum toxin type A, a prescription medicine that is injected into muscles and used in adults... Read More